



# Highnoon®

HNL/CS/1814  
August 15, 2022

**The General Manager,**  
Pakistan Stock Exchange Limited,  
Stock Exchange Building,  
Stock Exchange Road,  
**KARACHI.**

Subject: **FINANCIAL RESULTS FOR THE 2nd QUARTER**  
**ENDED JUNE 30, 2022**

Dear Sir,


This is to inform you that the Board of Directors of our Company in the meeting held on August 15, 2022 at 11.00 a.m. at registered office approved the accounts for the 2nd Quarter ended June 30, 2022.

**Financial Results of the Company and Consolidated Financial Results with its subsidiary are attached herewith as Annexure I and Annexure II respectively.**

The Quarterly Report of the Company for the period ended June 30, 2022 will be transmitted through PUCARS separately within the specified time.

Thanking you and assurances of our highest considerations.

Yours faithfully,

  
**KHADIM HUSSAIN MIRZA,**  
Company Secretary

- The Securities & Exchange Commission of Pakistan, Islamabad
- The Securities & Exchange Commission of Pakistan,  
Companies Registration Office, Lahore.
- Central Depository Company of Pakistan Limited, Karachi

**Highnoon Laboratories Limited: Registered Office & Plant:** 17.5 KM, Multan Road, Lahore - 53700, Pakistan.

**Corporate Office:** Office No. 901, 9th Floor, Tricon Corporate Center, 73 E, Jail Road, Lahore - 54660, Pakistan.

**UAN:** +92 (0) 304 111 0465 | **Phone:** +92 (42) 36407346 | **Fax:** 92 (42) 37510037 | **Email:** info@highnoon.com.pk | **URL:** www.highnoon-labs.com

**HIGHNOON LABORATORIES LIMITED**  
**UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)**  
**FOR THE SIX MONTHS ENDED 30 JUNE 2022**

	<b>Six Months Period Ended</b>		<b>Three Months Period Ended</b>	
	<b>30 June</b>	<b>30 June</b>	<b>30 June</b>	<b>30 June</b>
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
	<b>Rupees</b>	<b>Rupees</b>	<b>Rupees</b>	<b>Rupees</b>
Revenue from contracts with customers- net	8,083,729,768	6,369,964,698	4,327,695,401	3,252,878,543
Cost of revenue	(3,923,155,244)	(3,215,838,665)	(2,048,096,465)	(1,623,080,798)
<b>Gross Profit</b>	<b>4,160,574,525</b>	<b>3,154,126,033</b>	<b>2,279,598,937</b>	<b>1,629,797,745</b>
Distribution, selling and promotional expenses	(2,256,107,470)	(1,694,908,924)	(1,251,064,419)	(884,597,449)
Administrative and general expenses	(320,919,859)	(246,815,371)	(180,925,891)	(123,246,409)
Research and development expenses	(5,323,129)	(4,604,407)	(2,508,467)	(2,570,681)
Other operating expenses	(174,702,424)	(110,363,866)	(113,381,613)	(59,875,570)
	<b>(2,757,052,883)</b>	<b>(2,056,692,568)</b>	<b>(1,547,880,391)</b>	<b>(1,070,290,109)</b>
<b>Operating profit</b>	<b>1,403,521,642</b>	<b>1,097,433,465</b>	<b>731,718,546</b>	<b>559,507,636</b>
Other income	140,596,583	73,008,157	82,446,477	42,445,525
Finance costs	(15,209,676)	(14,803,247)	(13,867,477)	(7,378,873)
<b>Profit before taxation</b>	<b>1,528,908,549</b>	<b>1,155,638,375</b>	<b>800,297,546</b>	<b>594,574,288</b>
Taxation	(435,557,110)	(305,607,585)	(240,646,069)	(153,567,083)
<b>Profit for the period</b>	<b>1,093,351,438</b>	<b>850,030,790</b>	<b>559,651,476</b>	<b>441,007,205</b>
<b>Earnings per share - basic and diluted</b>	<b>26.10</b>	<b>Restated 20.29</b>	<b>13.36</b>	<b>Restated 11.58</b>




**Highnoon Laboratories Limited: Registered Office & Plant:** 17.5 KM, Multan Road, Lahore - 53700, Pakistan.

**Corporate Office:** Office No. 901, 9th Floor, Tricon Corporate Center, 73 E, Jail Road, Lahore - 54660, Pakistan.

**UAN:** +92 (0) 304 111 0 465 | **Phone:** +92 (42) 36407346 | **Fax:** 92 (42) 37510037 | **Email:** info@highnoon.com.pk | **URL:** www.highnoon-labs.com

**HIGHNOON LABORATORIES LIMITED**  
**CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)**  
**FOR THE SIX MONTHS ENDED 30 JUNE 2022**

	Six Month Period Ended		Three Month Period Ended	
	30 June 2022	30 June 2021	30 June 2022	30 June 2021
	Rupees	Rupees	Rupees	Rupees
Revenue from contract with customers- net	8,083,729,768	6,369,964,698	4,327,695,401	3,252,878,543
Cost of revenue	(3,845,819,179)	(3,155,732,362)	(1,993,691,794)	(1,598,207,306)
<b>Gross Profit</b>	<b>4,237,910,589</b>	<b>3,214,232,336</b>	<b>2,334,003,607</b>	<b>1,654,671,237</b>
Distribution, selling and promotional expenses	(2,256,107,470)	(1,694,908,924)	(1,251,064,419)	(884,597,449)
Administrative and general expenses	(346,377,837)	(266,335,130)	(195,071,704)	(132,296,729)
Research and development expenses	(5,323,129)	(4,604,407)	(2,508,467)	(2,570,681)
Other operating expenses	(178,552,472)	(112,310,576)	(115,836,833)	(60,984,997)
	(2,786,360,909)	(2,078,159,037)	(1,564,481,424)	(1,080,449,856)
<b>Operating profit</b>	<b>1,451,549,681</b>	<b>1,136,073,299</b>	<b>769,522,184</b>	<b>574,221,381</b>
Other income	140,047,595	72,585,602	81,971,092	42,390,460
Finance costs	(17,748,660)	(18,486,455)	(14,768,663)	(9,107,267)
<b>Profit before taxation</b>	<b>1,573,848,616</b>	<b>1,190,172,446</b>	<b>836,724,613</b>	<b>607,504,574</b>
Taxation	(451,875,774)	(312,101,684)	(253,078,897)	(156,818,760)
<b>Profit for the period</b>	<b>1,121,972,841</b>	<b>878,070,762</b>	<b>583,645,715</b>	<b>450,685,814</b>